Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Q3 2025 Earnings Presentation
10 slides from Aquestive Therapeutics's earnings presentation, Nov 6, 2025
Slide 1: Third Quarter 2025 Earnings Supplemental Materials
Third Quarter 2025 Earnings Supplemental Materials September 2024 November 5, 2025 Advancing medicines. Solving problems. Improving lives.
Slide 2: Disclaimer
Disclaimer Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and simil
Slide 3: Q3 2025 earnings key messages
Q3 2025 earnings key messages Anaphylm (dibutepinephrine) Sublingual Film for severe allergic reactions, including anaphylaxis • U.S. Food and Drug Administration (FDA) confirms that it will not require an Advisory Committee to review the Company’s New Drug Application for Anaphylm • Preparing for a
Slide 4: Q3 2025 earnings key messages - continued
Q3 2025 earnings key messages - continued AQST-108 and the expansion of AdrenaVerse platform • Plan to open Investigational New Drug application for AQST-108 with FDA in Q4 2025 • Expect to initiate a clinical study for AQST-108 for Alopecia Areata in 1H 2026 • Strengthened clinical leadership to re
Slide 5: Upcoming expected key milestones
Upcoming expected key milestones Potential ex-U.S. Regulatory Filings AnaphlymTM PDUFA action date is scheduled for January 31, 2026 AQST – 108 Expect to submit IND Expect to initiate clinical study Libervant® Expected licensee-led U.K. regulatory approval1 Q4 2025 Q1 2026 Q2 2026 Q3 2026 1. License
Slide 6: Third Quarter Results
| << Aquestive’ Third Quarter Results
Slide 7: Ending Cash Balance by Quarter
Expected to meet near-term milestones with projected cash runway into 2027 Ending Cash Balance by Quarter $129.1 120 100 $93.0 USD (Millions) 80 $68.7 $60.5 60 40 20 0 Q4 24 Q1 25 Q2 25 Q3 25 7
Slide 8: Manufacturing operations continue to generate cash
Manufacturing operations continue to generate cash Doses Shipped by Quarter 60,000 50,000 47,953 46,241 45,328 43,818 43,801 DOSES SHIPPED (000’S) 42,516 43,032 40,000 37,204 33,458 34,418 30,000 27,392 20,000 10,000 0 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 QUARTER 8
Slide 9: 2025 guidance as of November 5, 2025
2025 guidance as of November 5, 2025 2025 Outlook • Total revenues of approximately $44-$50 million • Non-GAAP adjusted EBITDA loss of approximately $47-$51 million 9
Slide 10: Thank You
| << Aquestive’ Thank You
Aquestive Therapeutics — Q3 2025 Earnings Presentation on 6ix